111726-43-3

Basic information

• Product Name: 1,3-Benzodioxole, 5-(methoxymethoxy)-
• Synonyms: 1,3-Benzodioxole, 5-(methoxymethoxy)-;5-(Methoxymethoxy)benzo[d][1,3]dioxole
• CAS NO: 111726-43-3
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.1733
• Mol File: 111726-43-3.mol

Chemical Properties

• Boiling Point: 260.6±28.0 °C(Predicted)
• Appearance: /
• Density: 1.235±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,3-Benzodioxole, 5-(methoxymethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzodioxole, 5-(methoxymethoxy)-(111726-43-3)
• EPA Substance Registry System: 1,3-Benzodioxole, 5-(methoxymethoxy)-(111726-43-3)

Safety Data

• Hazardous Substances Data: 111726-43-3(Hazardous Substances Data)

Usage

Physical state

Colorless liquid

Odor

Faint

Uses

a. Production of fragrances and flavoring agents
b. Synthesis of pharmaceutical drugs
c. Solvent for various industrial applications

Characteristics

Enhances aromatic and sweet properties of other substances

Safety concerns

Potential health and safety risks if not handled properly

Upstream product

• 533-31-3 Sesamol 
• 107-30-2 chloromethyl methyl ether 
• 542-88-1 bis(2-chloromethyl)ether 
• 13057-17-5 bromethyl methyl ether 
• 120-57-0 piperonal 
• 80592-18-3 3,4-methylenedioxyphenyl formate 

Downstream Products

• 484-31-1 dillapiole 
• 316800-21-2 5-hydroxy-4-phenylthio-1,3-benzodioxole 
• 316800-20-1 5-hydroxy-4-phenylmethylthio-1,3-benzodioxole 
• 316800-25-6 5-allyloxy-4-phenylthio-1,3-benzodioxole 
• 316800-22-3 5-hydroxy-4-(4'-methoxyphenylthio)-1,3-benzodioxole 
• 316800-34-7 5-methoxy-4-phenylthio-6-(2-propenyl)-1,3-benzodioxole 
• 316800-24-5 5-allyloxy-4-phenylmethylthio-1,3-benzodioxole 
• 316800-31-4 5-hydroxy-4-phenylthio-6-(2-propenyl)-1,3-benzodioxole 
• 316800-26-7 5-allyloxy-4-(4'-methoxyphenylthio)-1,3-benzodioxole 
• 316800-30-3 5-hydroxy-4-phenylmethylthio-6-(2-propenyl)-1,3-benzodioxole 
• 316800-33-6 5-methoxy-4-phenylmethanethio-6-(2-propenyl)-1,3-benzodioxole 
• 316800-32-5 5-hydroxy-4-(4'-methoxyphenylthio)-6-(2-propenyl)-1,3-benzodioxole 
• 849517-65-3 4-iodobenzo[d][1,3]dioxole 
• 442663-29-8 (2-(3-benzyloxy-2-iodo-4-methoxy-5-methyl-phenyl)-1-{[2-(tert-butyl-diphenyl-silanyloxy)-1-(6-methoxymethoxy-7-methyl-benzo[1,3]dioxol-4-yl)-ethyl]-[1-(4-methoxy-phenylcarbamoyl)-ethyl]-carbamoyl}-ethyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant

A series of A-ring-modified lamellarin N analogues were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer. Several water-soluble ammonium- or guanidinium-tethered analogues exhibited good kinase inhibitory activities. The most promising analogue, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM]. The effects of A-ring-substituents on activity were rationalized by docking studies.

TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND

Disclosed is a series of tricyclic substituted piperidine dione compounds, and applications thereof in the preparation of medicines for treating diseases related to CRBN protein; specifically disclosed are the derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Enantioselective Ni-Catalyzed Electrochemical Synthesis of Biaryl Atropisomers

A scalable enantioselective nickel-catalyzed electrochemical reductive homocoupling of aryl bromides has been developed, affording enantioenriched axially chiral biaryls in good yield under mild conditions using electricity as a reductant in an undivided cell. Common metal reductants such as Mn or Zn powder resulted in significantly lower yields in the absence of electric current under otherwise identical conditions, underscoring the enhanced reactivity provided by the combination of transition metal catalysis and electrochemistry.

Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities

Microtubule has been an important target for anticancer drug development. Here we report the discovery and characterization of a series of fused 4-aryl-4H-chromene-based derivatives as highly potent microtubule inhibitors. Among a total of 37 derivatives synthesized, 23 exhibited strong in vitro anti-proliferative activities against A375 human melanoma cells. The relationship between the biological activities of these microtubule inhibitors and their chemical structure variations was analyzed. Studies of compounds 27a, 19a and 9a in parallel with colchicine as the positive control compound in a panel of biological assays revealed that these compounds blocked cell cycle progression, increased apoptosis, and inhibited HUVEC capillary tube formation at low nanomolar concentrations. The most potent compound 27a was also tested in eight additional cancer cell lines besides A375 cells and two non-cancer cells and showed potent and selective activity on these cancer cells. To understand the molecular and structure mechanism of action of these compounds, tubulin polymerization and molecular docking studies were carried out for 27a as the representative. The results were consistent with the mechanism by which 27a interacts with the colchicine binding site on tubulin and disrupts tubulin polymerization. With potent dual actions of microtubule destabilization and vascular disruption described above, this small molecule can serve as a valuable research probe of the function and role of microtubules in human diseases and promising lead for developing new therapeutic agents.

HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Synthesis and structure revision of goupiolone A: A benzotropolone natural product

Goupiolone A, a benzotropolone natural product, has been synthesized by assembling a benzocyclobutene derivative and a silyl-substituted cyclopropane unit, followed by thermal ring enlargement. The synthetic sample did not correspond to the reported data. On the basis of biogenetic considerations, an alternative structure with a catechol moiety was proposed, and the synthesis established it as the correct structure.

Sporolide B: Synthetic studies

Studies directed toward the synthesis of the architecturally complex marine natural product sporolide B are described. Synthetic analysis suggested advanced hydroquinone and benzodiquinane fragments, which upon elaboration were successfully united via an

Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: Heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay

Heat shock protein 90 is emerging as an important target in cancer chemotherapy. In a program directed toward identifying novel chemical probes for Hsp90, we found N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)benzene sulfonamide as an Hsp90 inhibitor with very weak activity. In this report, we present a new and general method for the synthesis of a variety of analogs around this scaffold, and discuss their structure-activity relationships.